BioSpace News Archive

Transparency Market Research has published a new report titled, ‘Diabetes Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

JOYSBIO, one of the world’s leading manufacturers of COVID-19 tests, announces their tests are available everywhere and identifies new, dangerous variants.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global artificial limbs market size would reach US$ 630 million by 2025 and is expected to grow at a healthy CAGR of 6% between 2020 and 2025.

Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab and AB308 from Arcus Biosciences, in Japan and certain other territories in Asia.

Immunovia AB announced that the Company’s President and Chief Executive Officer, Patrik Dahlen, has informed the Board of Directors of his intention to step down, for personal reasons.

A three-year study of more than 1,000 patients found that the risk of delayed intracranial hemorrhage and death following head trauma was significantly higher for adults taking older blood thinning medications including clopidogrel and warfarin, according to research being presented at the annual meeting of the Radiological Society of North America.

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in December 2021.

LYNPARZA ® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer.

Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced it has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis.